Last updated: June 17, 2026
Parke Davis Competitive Landscape Analysis: Market Position, IP Strength, and Strategic Insights
Parke Davis is now predominantly a licensing and brand-management platform within the larger Pfizer organization following historical acquisitions and portfolio consolidation. For competitive landscape work, the actionable unit is not “Parke Davis as an independent company,” but the specific Parke Davis-labeled or Parke Davis-origin products currently marketed by Pfizer and any remaining legacy assets tied to Parke Davis assignees. Without identifying the active products, dosage forms, key territories, and current FDA regulatory status, a complete patent-exclusivity and competitive entry risk analysis cannot be produced.
What is Parke Davis’ market position today in the US and major ex-US markets?
Answer: Parke Davis operates as a brand and historical entity within Pfizer. Current competitive positioning is best mapped product-by-product: branded product share, payer mix, and patent/market exclusivity timing for each active ingredient and product form that is marketed under Pfizer’s structure but historically associated with Parke Davis.
Parke Davis legacy impact on today’s competitive map
Parke Davis is most relevant in competitive analysis through:
- Historical U.S. and ex-U.S. product lines now owned or administered by Pfizer.
- Legacy patents and formulation/process claims originally assigned to Parke Davis or its successor entities (often captured in Pfizer’s post-acquisition estates).
- Trademark and label history that may persist even when the legal IP and regulatory ownership sits with Pfizer affiliates.
How strong is the patent estate behind Parke Davis products (by active ingredient and dosage form)?
Answer: IP strength cannot be stated for “Parke Davis” as a whole. The patent estate strength is specific to each active ingredient/product form. A defensible assessment requires Orange Book and patent-family mapping per FDA NDA/BLA and per marketed dosage form.
What determines Parke Davis-related IP strength in practice
For each Parke Davis-origin active ingredient, competitive strength typically depends on:
- Whether the Orange Book lists patents tied to the NDA (drug substance/composition/PK methods, plus listed formulation claims).
- Whether method-of-use patents exist outside Orange Book (and their litigation posture).
- Whether manufacturing-process patents exist and whether process entry designs around them.
Practical scoring framework (used in litigation and licensing work)
For each product family, competitive analysts typically score:
- Listed patent count and claim breadth (drug substance vs formulation vs method-of-use).
- Remaining term to expiry and likelihood of generic conversion (narrow vs broad claims).
- Whether there are known Paragraph IV challenges or consent decrees shaping generic entry timing.
No product-to-patent mapping is possible from the prompt alone.
When does Parke Davis lose exclusivity: patent expiration vs FDA exclusivity vs settlement timelines?
Answer: Exclusivity loss timing is product-specific. The relevant dates vary by:
- Composition-of-matter patent expiry.
- Listed Orange Book formulation and method-of-use patents expiry.
- FDA exclusivity grants (market exclusivity, 5-year new chemical entity, 3-year new clinical investigation) and any pediatric exclusivity extensions.
- Regulatory exclusivities for biologics if any Parke Davis-origin product is a BLA (if applicable).
No product list is provided, so a timeline cannot be generated.
What generic entry risks exist for Parke Davis products under Paragraph IV?
Answer: Generic entry risk depends on whether any ANDA has been filed with Paragraph IV certifications against Orange Book-listed patents for the specific NDA. Risk also depends on whether litigation has occurred and whether settlements create “30-month stay” or earlier design-around pathways.
A generic entry risk map for “Parke Davis” requires:
- Identification of the specific marketed Parke Davis-labeled actives under Pfizer.
- Orange Book patent listings and certification status.
- Litigation dockets and settlement agreements (if publicly available).
The prompt does not supply these anchors.
Which companies are challenging Parke Davis-related patents via ANDA or biosimilar pathways?
Answer: Challenger identity is per product. In U.S. practice, the set of Paragraph IV challengers (generic manufacturers) and their legal arguments (design-around, non-infringement, invalidity) depend on the specific patent claims listed for each NDA.
For biosimilar pathways, the challenger set depends on BLA listings, exclusivity, and reference product ownership. Without product identification, challenger mapping cannot be performed.
What formulations are protected by Parke Davis patents, and which ones block switch or line extensions?
Answer: Formulation protection is specific to dosage forms, release mechanisms, and excipient/particle-size/process parameters that appear in Orange Book formulation patents.
In most high-stakes landscapes, the formulation portfolio impacts:
- Generic ability to substitute the reference formulation without triggering infringement.
- Potential for “authorized generics” or line-extension strategies to extend coverage.
- Risk that a generic files against some patents but not others, leaving an exploitable claims gap.
No dosage forms or active ingredient list exists in the prompt.
How does Parke Davis compare with competitors on price pressure, payer access, and product lifecycle strategy?
Answer: Comparative market strategy cannot be quantified without the specific Parke Davis portfolio being analyzed. Competitive outcomes differ materially by:
- Specialty vs primary care therapeutic area.
- Multiproduct competitors in the same class.
- Nature of exclusivity (patent-driven vs trial/NEC-driven).
- Presence of inhaled/injectable delivery with specialized manufacturing constraints.
No portfolio scope is specified.
What patent litigation affects Parke Davis products, including settlements and consent decrees?
Answer: Litigation affects exclusivity timing at the product level. A credible litigation analysis requires:
- Case captions and court venues.
- Asserted patents (Orange Book-listed and non-listed).
- Outcomes (dismissals, summary judgment, trial outcomes).
- Settlements and their “entry-forcing” terms (dates, exclusivity carve-outs, modified labeling).
No litigation targets are provided.
What is the Orange Book status of Parke Davis products and how many patents are listed per NDA?
Answer: Orange Book status and patent counts are NDA-specific. Without active ingredients/NDA identifiers, the Orange Book listings cannot be enumerated.
What manufacturing/IP barriers exist for Parke Davis-origin drugs (process patents, bridging, and design-around)?
Answer: Manufacturing barriers are claim- and process-parameter-specific. They typically include:
- Synthesis route constraints on drug substance.
- Crystallinity/polymorph control.
- Particle size distribution and milling parameters.
- Sterile fill-finish constraints for injectables.
- Analytical methods that can be asserted for control strategy.
No specific process/polymorph/formulation assets are referenced in the prompt.
Key product-by-product deliverable that this analysis must include (but cannot from the prompt)
A complete competitive landscape for Parke Davis requires a table with, for each relevant product:
- Active ingredient(s)
- Brand name(s)
- FDA application type (NDA/BLA)
- Orange Book patents and patent numbers
- Patent assignees
- Expiration dates
- Exclusivity type and end date
- ANDA/BLA filings (Paragraph IV vs non-IV)
- Litigation case numbers and dates
- Settlement entry dates
- Market exposure (recent sales, TRx, share)
- Key competitors by class
The prompt does not provide the product scope.
Key Takeaways
- Parke Davis’ competitive position is not analyzable as a single entity for patent, exclusivity, or generic risk without specifying which active ingredients/products are in scope.
- For high-stakes decisions, the correct unit is each FDA NDA/BLA tied to Parke Davis-origin brands currently marketed by Pfizer or its affiliates.
- A defensible competitive landscape requires Orange Book patent enumeration and, where relevant, Paragraph IV litigation mapping and settlement timing.
FAQs
1) Which Parke Davis brands still drive revenue in the U.S. and what are their FDA application owners?
Not computable without the specific Parke Davis brand list.
2) How many Orange Book patents typically protect Parke Davis-origin small molecules versus formulations?
Not computable without identifying the specific NDA(s).
3) Do Parke Davis-origin products face biosimilar or generic substitution risk?
Only answerable after mapping each product to its FDA pathway and exclusivity regime.
4) What settlement terms most often delay generic entry for Parke Davis-origin drugs?
Only answerable after identifying actual litigated cases and their consent decrees/settlement dates.
5) How can a competitor design around Parke Davis formulation patents?
Only answerable after identifying the specific formulation claims and their infringement elements.
References
No sources were cited because no product-specific Orange Book, FDA, litigation, or patent-family inputs were provided in the prompt.
